A federal district judge has dismissed two community health centers’ federal and state antitrust claims against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Chief Judge Elizabeth Wolford of
…
A federal district judge on Wednesday continued the stay in community health centers’ lawsuit against federal health officials over the administrative dispute resolution process for the 340B program after accepting the explanation for a missed deadline to file a report
…
A federal district judge in Washington, D.C., yesterday ordered community health centers to answer why she should not dismiss their lawsuit against federal health officials over the administrative dispute resolution process for the 340B program.
Judge Florence Pan of U.S.
…
The potential cost to the U.S. government next year of remedying unlawful Medicare Part B drug payment cuts for 340B hospitals could be higher than federal Medicare officials think.
The U.S. Centers for Medicare & Medicaid Services in mid-July put
…
A federal district judge on Tuesday gave federal health officials a Sept. 22 deadline to respond to a higher court’s ruling last month that a South Carolina health center has the right to challenge the legality of the government’s 340B
…
Correction, Friday, Aug. 26, 2022, 3:00 p.m. EDT—The original version of this article mistakenly said the hospital plaintiffs’ complaint stated that HHS improperly based 2020 and 2021 Medicare Part B drug payment cuts for 340B hospitals on a survey of
…
Federal health officials should not be allowed to craft their own plan to remedy unlawful Medicare Part B drug payments cuts for 340B hospitals since 2018, as the government has not shown how it would stop future illegal payment cuts,
…
A federal district judge has accepted a plan that might speed up a decision in the drug industry’s lawsuit challenging an Arkansas law that requires drug makers to honor 340B contract pharmacy arrangements.
U.S. Senior District Judge Billy Roy Wilson
…
The U.S. government and drug makers Novartis and United Therapeutics’ cross-appeals in their 340B contract pharmacy legal dispute have been set for oral arguments in October, marking the first of the closely watched lawsuits to advance to oral arguments at
…
The federal government during the past week filed responses to arguments that drug manufacturers AstraZeneca and Lilly made in federal appeals courts in their 340B contract pharmacy lawsuits.
“In enacting the 340B program, Congress was clear that drug manufacturers must
…*Sign up for news summaries and alerts from 340B Report